Abstract:You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology III1 Apr 2018MP88-16 THE DOWNREGULATION AND TUMOR SUPPRESSIVE FUNCTION OF RASAL2 IN RENAL CELL CARCINOMA Ke Hui, Kaijie Wu, Jer-Tsong Hsieh, and Dalin He Ke HuiKe Hui More articles by this author , Kaijie WuKaijie Wu More articles by this author , Jer-Tsong HsiehJer-Tsong Hsieh More articles by this author , and Dalin HeDalin He More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2936AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Patients with renal cell carcinoma (RCC) often develop resistance to anti-vascular drug and eventually succumb to disease. However, the underlying molecular mechanism of drug resistance remains poorly understood. In this study, we demonstrated that RASAL2, a RAS GTPase activating protein (RASGAP), played suppressive role in in RCC by targeting tumor angiogenesis. METHODS RCC and its paired normal kidney tissues were immunohistochemically stained for RASAL2 expression. Databases downloaded from TCGA or GEO were used to analyze the methylation status of RASAL2 and the correlation between RASAL2 and c-FOS or VEGFA in RCC tissues. In vitro, RASAL2 gain-function in 786-O cells or loss-function in ACHN cells were measured for the recruitment and tube formation of human umbilical vein endothelial cell (HUVEC) by HUVEC migration assay and tube formation assay, ELISA assay and western blot analysis. In vivo, subcutaneous xenografts in nude mice were used to detect tunorigenicity. Moreover, the expression of RASAL2, VEGFA and CD31 in RCC tissues and xenografts were detect by immunohistochemical (IHC) staining. RESULTS The expression of RASAL2 was downregulated in RCC tissues, and RASAL2 mRNA was inversely correlated with RASAL2 methylation or c-FOS mRNA or VEGFA mRNA in RCC tissues. Overexpression of RASAL2 in 786-O cells could inhibit the recruitment and tube formation of HUVECs, while RASAL2 knockdown (KD) in ACHN cells enhanced the recruitment and tube formation of HUVECs in vitro. Also, overexpression of RASAL2 could inhibit tumorigenecity of xenografts. Mechanistically, RASAL2 KD could enhance the phosphorylation of GSK3 and upregulate the expression of c-FOS and VEGFA. Furthermore, RASAL2 was inversely correlated with VEGFA and CD31 in tissues from human RCC specimens and xenografts. CONCLUSIONS RASAL2 was downregulated in RCC tissues, which could lead to tumor angiogenesis via p-GSK3/c-FOS/VEGFA signaling pathway. Therefore, RASAL2 could be a potential target to prevent patients with RCC from resistance to anti-vascular therapy. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1203-e1204 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Ke Hui More articles by this author Kaijie Wu More articles by this author Jer-Tsong Hsieh More articles by this author Dalin He More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Upregulation of RASAL2 Promotes Proliferation and Metastasis, and is Targeted by Mir-203 in Hepatocellular Carcinoma.

MicroRNA-302d Downregulates TGFBR2 Expression and Promotes Hepatocellular Carcinoma Growth and Invasion.

[Expression of RASAL2 in hepatocellular carcinoma and the clinical significance].

Mir‑654‑3p Suppresses Cell Viability and Promotes Apoptosis by Targeting RASAL2 in Non‑small‑cell Lung Cancer.

Downregulation of Rasal2 Promotes the Proliferation, Epithelial-Mesenchymal Transition and Metastasis of Colorectal Cancer Cells

Ras-association Domain Family 10 Acts As a Novel Tumor Suppressor Through Modulating MMP2 in Hepatocarcinoma

Mp88-16 the downregulation and tumor suppressive function of rasal2 in renal cell carcinoma

The Expression and Function of RASAL2 in Renal Cell Carcinoma Angiogenesis

RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.

Downregulation Of Mir-200a Induces Emt Phenotypes And Csc-Like Signatures Through Targeting The Beta-Catenin Pathway In Hepatic Oval Cells

RASAL2 Promotes Tumor Progression Through LATS2/YAP1 Axis of Hippo Signaling Pathway in Colorectal Cancer.

Down-Regulation Of Mir-146b-5p By Long Noncoding Rna Malat1 In Hepatocellular Carcinoma Promotes Cancer Growth And Metastasis

Microrna-200a Inhibits Cell Growth and Metastasis by Targeting Foxa2 in Hepatocellular Carcinoma

MALAT1/ miR-1-3p-mediated BRF2 promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway

RALBP1 Regulates Oral Cancer Cells Via Akt and is a Novel Target of Mir-148A-3p and Mir-148B-3p.

Data from Mirna-487A Promotes Proliferation and Metastasis in Hepatocellular Carcinoma

MicroRNA-30a Suppresses Tumor Progression by Blocking Ras/Raf/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma.

miR-671-5p Promotes Cell Proliferation, Invasion, and Migration in Hepatocellular Carcinoma through Targeting ALDH2

The Long Non-Coding RNA CASC2 Suppresses Cell Viability, Migration, and Invasion in Hepatocellular Carcinoma Cells by Directly Downregulating Mir-183

MALAT1/ mir-1-3p mediated BRF2 expression promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway

Mir-130B-5p Promotes Proliferation, Migration and Invasion of Gastric Cancer Cells Via Targeting RASAL1